Compare Mondaycom Ltd (MNDY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs BIO-TECHNE Corp — how do they compare? Mondaycom Ltd trades at $88.99 (market cap $3.53B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 3.2× Mondaycom Ltd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and BIO-TECHNE Corp for 63 Days on average.
| MNDY | TECH | |
|---|---|---|
Market Cap | $3.53B | $11.37B |
Volume | 583,371 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $205.24 | $72.61 |
52-Week Low | $58.81 | $43.31 |
Typical Hold Time | 16 Days | 63 Days |
Enterprise Value | $2.69B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $83.51, down 0.93% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with revenue growth from $1.2B in 2025 to $1.4B in 2026 and consistent earnings beats. Recent news highlights its inclusion in growth stock lists and an upcoming AI-focused conference, Elevate '26.
The outlook is positive given analyst consensus of $110.42 price target and 65% buy ratings, but risks include competitive pressure from Meta's enterprise push and volatile cash flow trends. Investment appeal hinges on execution of AI initiatives and high-value client growth against premium valuations.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
